Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced Head and Neck Squamous Cell Carcinoma. A Single Arm, Open Label, Multicenter Phase II Trial.
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2017
At a glance
- Drugs Cancer vaccine (Primary)
- Indications Head and neck cancer; Lung cancer; Ovarian cancer; Pancreatic cancer
- Focus Therapeutic Use
- 27 Jun 2017 Status changed from not yet recruiting to recruiting.
- 03 Mar 2017 Planned initiation date changed from 1 Mar 2017 to 1 Jun 2017.
- 19 Dec 2016 Status changed from planning to not yet recruiting.